# US 2025/0144256 A1 · Albumin Conjugates and Process for Preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144256 A1
- Document ID: US20250144256A1
- Status: Published application
- Kind: A1
- Application number: 18/940,433
- Filed: 2024-11-07
- Published: 2025-05-08
- Earliest claimed: 2023-11-08
- Assignees: Jubilant Draximage Inc.
- Applicants: Jubilant Draximage Inc.
- Inventors: Indranil NANDI; Vijayaraj Kuniyil KULANGARA; Miriam Ruiz PENA; Aida Mary Abreu DIAZ; Arundhati BHATTACHARYYA; Dinesh Kumar SARWAL
- Web page: https://patentgrep.com/patent/US20250144256A1

## CPC

- A61K 51/1241: {particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/385: {Serum albumin}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 51/081: {the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61B 6/4057: {by using radiation sources located in the interior of the body (A61B6/037 takes precedence)}
- A61J 1/065: {Rigid ampoules, e.g. glass ampoules}
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE

## Abstract

The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.

## Claims

### Claim 1

A sterile, non-pyrogenic, lyophilised pharmaceutical composition, comprising:
i) macroaggregated albumin;
ii) a reducing agent;
iii) human serum albumin; and
iv) an isotonicity agent;
wherein the macroaggregated albumin is stannous incorporated macroaggregated albumin and wherein the average particle size of the macroaggregated albumin particles is 20 μm to 35 μm when measured by optical microscopy and/or automated microscopy and image analysis.

### Claim 2 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the average particle size is 25 to 35 μm and at least 95% of the macroaggregated albumin particles are between 10 μm to 70 μm, less than 3% of the macroaggregated albumin particles are below 10 μm and none of the macroaggregated albumin particles are above 100 μm and have not more than 3% soluble and dispersed human serum albumin content, when measured by optical microscopy and/or automated microscopy and image analysis.

### Claim 3 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the macroaggregated albumin particles have not more than 3% soluble and dispersed human serum albumin impurities content, when measured by optical microscopy and/or automated microscopy and image analysis.

### Claim 4 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the pH of the composition when reconstituted with a 0.9% w/v sodium chloride solution is 5.0-7.0.

### Claim 5 (depends on 1)

The lyophilised pharmaceutical composition of claim 1, wherein the composition comprises macroaggregated and human serum albumin in a ratio of 1:5 to 1:25.

### Claim 6 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein, the bacterial endotoxin content of the composition is not more than 20 EU/vial.

### Claim 7 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the composition is contained in a vial comprising an oxygen content of less than 5 percent in the head space.

### Claim 8 (depends on 1)

The lyophilised pharmaceutical composition of claim 1, wherein the isotonicity agent is sodium chloride.

### Claim 9 (depends on 1)

The lyophilised pharmaceutical composition of claim 1, wherein the reducing agent is selected from stannous chloride, stannous fluoride, and combinations thereof.

### Claim 10 (depends on 1)

The lyophilised pharmaceutical composition of claim 1, wherein the macroaggregated albumin is prepared by an automated manufacturing process in a suitable reactor.

### Claim 11 (depends on 1)

A kit comprising the pharmaceutical composition of claim 1, wherein the kit comprises a clinical grade container selected from vials, syringes, ampoules, and pre-filled syringes.

### Claim 12 (depends on 11)

The kit of claim 11, wherein the kit comprises a glass vial of capacity 3 mL to 30 mL.

### Claim 13 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the particle size and particle density is maintained at the initial value for at least 2 years of storage at about 25° C.

### Claim 14 (depends on 1)

The lyophilized pharmaceutical composition of claim 1, wherein the pH after reconstitution with a 0.9% sodium chloride solution does not show a drift of more than 0.5 for at least 2 years of storage at about 25° C.

### Claim 15 (depends on 1)

The lyophilised pharmaceutical composition of claim 1, wherein the composition is a single dose composition comprising:
i) about 0.02 mg macroaggregated albumin;
ii) not less than 5 μg of stannous chloride;
iii) about 1.0 mg human serum albumin; and
iv) about 0.09-0.15 mg sodium chloride;
wherein the macroaggregated albumin is stannous incorporated macroaggregated albumin and wherein the average particle size of the macroaggregated albumin particles is 25-35 μm, 95% of the macroaggregated albumin particles are between 10-70 μm, less than 3% of the particles are below 10 μm and none of the particles are above 100 μm, when measured by optical microscopy and/or automated microscopy and image analysis;
wherein the composition comprises 300,000 to 800,000 macroaggregated albumin particles; and wherein the total tin content of the composition is not more than 13 μg;
wherein the pH of the composition when reconstituted with a 0.9% w/v sodium chloride solution is in the range of 5.0-7.0; and
wherein the bacterial endotoxin content is less than 20 EU/vial; and
wherein the composition is contained in a vial comprising an oxygen content of less than 5 percent in the head space.

### Claim 16

A reconstituted radiopharmaceutical composition, comprising:
(i) a first component comprising an aqueous solution of 99mTc pertechnetate and
(ii) a second component comprising a lyophilised pharmaceutical composition comprising:
a) macroaggregated albumin,
b) a reducing agent,
c) human serum albumin, and
d) an isotonicity agent,
wherein the macroaggregated albumin is stannated macroaggregated albumin having a particle density in the range of 300,000-700,000 particles in a unit dose and wherein the average particle size of the macroaggregated albumin particles is 25-35 μm, at least 95% of the macroaggregated albumin particles are between 10-70 μm, not more than 3% of the macroaggregated albumin particles are below 10 μm and none of the macroaggregated albumin particles are above 100 μm, when measured by optical microscopy and/or automated microscopy and image analysis; and wherein it comprises not more than 3% soluble and dispersed radiochemical impurities.

### Claim 17 (depends on 16)

The reconstituted radiopharmaceutical composition of claim 16, wherein the composition comprises radioactivity in the range of 20 to 500 megabecquerels (MBq).

### Claim 18 (depends on 16)

A process for the preparation of the radiopharmaceutical composition of claim 16, comprising:
reconstituting a lyophilized composition of i) macroaggregated albumin; ii) a reducing agent; iii) human serum albumin; and iv) an isotonicity agent, wherein the macroaggregated albumin is stannous incorporated macroaggregated albumin and wherein the average particle size of the macroaggregated albumin particles is 20 μm to 35 μm when measured by optical microscopy and/or automated microscopy and image analysis, with (a) a sterile solution of 99mTc-pertechnetate or (b) first a biocompatible carrier followed by a sterile solution of 99mTc pertechnetate.

### Claim 19 (depends on 16)

The reconstituted radiopharmaceutical composition of claim 16, wherein the composition has a radiochemical purity of at least 99% for at least 12 hours when stored at a temperature of 2° C. to 8° C.

### Claim 20 (depends on 16)

The reconstituted radiopharmaceutical composition of claim 16, wherein not more than 10% of the total radioactivity is found in the supernatant liquid after centrifugation of the composition at about 2000 rpm for 5-10 minutes.

### Claim 21 (depends on 16)

The reconstituted radiopharmaceutical composition of claim 16, wherein not less than 85.0% of the radioactivity is found in the lungs, not more than 2.0% of the radioactivity is found in the liver, and not more than 2.0% of the radioactivity is found in the kidneys in not less than two of the animals, when the said reconstituted injection is injected into three suitable animals selected from mice and rats.

### Claim 22 (depends on 16)

The reconstituted radiopharmaceutical composition of claim 16, wherein the volume of a single dose is from about 0.1 mL to 3 mL.

### Claim 23 (depends on 16)

A process for preparing the reconstituted radiopharmaceutical composition of claim 16, comprising the steps of:
i) preparing stannous macroaggregated albumin (Sn-MAA) by
ia) mixing human serum albumin with saline solution;
ib) adjusting the pH to between 8.0 to 12.0 with stirring at a rate of 200 to 500 rpm at suitable temperature;
ic) cooling to 20 to 25° C. with stirring at a rate of 200 to 400 rpm;
id) adjusting the pH to 2.0 to 5.0 and sterile filtering the solution to obtain filtrate;
ie) adjusting the pH of the filtrate to 4.0 to 6.0;
if) heating the solution at 50 to 80° C. with stirring at stirring a rate of 200 to 400 rpm and cooling to obtain macroaggregated albumin; and
ig) reacting the macroaggregated albumin with stannous chloride to obtain stannated macroaggregated albumin (Sn-MAA);
ii) lyophilizing stannated macroaggregated albumin by
iia) diluting the stannated macroaggregated albumin (Sn-MAA) with water and adding human serum albumin;
iib) lyophilizing the reaction mixture of step iia); and
iii) reconstituting the lyophilized serum with an aqueous 99mTc pertechnetate solution;
wherein steps ia) to ig) are carried out as automated continuous process.

### Claim 24 (depends on 23)

The process of claim 23, wherein the process does not comprise initial purification of the albumin solution used as starting material; and, wherein the process does not comprise separation of the stannous incorporated macroaggregated albumin particles and passing the same through a sizing screen.

### Claim 25 (depends on 23)

The process of claim 23, wherein the albumin concentration at step ia) is 0.5% w/v to 3.0% w/v.

### Claim 26 (depends on 23)

The process of claim 23, wherein the filtrate at step id) is a colloidal solution with average particle size between 10 nm to 50 nm.
